Detalles de la búsqueda
1.
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21266704
2.
A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21262027
3.
Syncytia formation by SARS-CoV-2 infected cells
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-202028
4.
Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-455901
5.
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277885
6.
SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20140178
7.
Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-442916
8.
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430472
9.
SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-328369
10.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516888
11.
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-475248
12.
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-462234
13.
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-445838
14.
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257393
15.
Evolution of human antibody responses up to one year after SARS-CoV-2 infection
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256823
16.
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261766
17.
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261769
18.
Distinct systemic and mucosal immune responses to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21251633
19.
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22278699
20.
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20230508